BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8648382)

  • 1. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
    McLaughlin P; Hagemeister FB; Romaguera JE; Sarris AH; Pate O; Younes A; Swan F; Keating M; Cabanillas F
    J Clin Oncol; 1996 Apr; 14(4):1262-8. PubMed ID: 8648382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
    Tsimberidou AM; Younes A; Romaguera J; Hagemeister FB; Rodriguez MA; Feng L; Ayala A; Smith TL; Cabanillas F; McLaughlin P
    Cancer; 2005 Jul; 104(2):345-53. PubMed ID: 15948158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.
    McLaughlin P; Hagemeister FB; Swan F; Cabanillas F; Pate O; Romaguera JE; Rodriguez MA; Redman JR; Keating M
    J Clin Oncol; 1994 Mar; 12(3):575-9. PubMed ID: 8120556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
    Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
    Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of mitoxantrone in the treatment of indolent lymphomas.
    Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
    Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.
    Shin DY; Kim SJ; Yoon DH; Park Y; Kong JH; Kim JA; Kim BS; Kim HJ; Won JH; Park SK; Kim WS
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):865-73. PubMed ID: 26984211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
    McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
    Seymour JF; Grigg AP; Szer J; Fox RM
    Ann Oncol; 2001 Oct; 12(10):1455-60. PubMed ID: 11762819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
    Tsimberidou AM; McLaughlin P; Younes A; Rodriguez MA; Hagemeister FB; Sarris A; Romaguera J; Hess M; Smith TL; Yang Y; Ayala A; Preti A; Lee MS; Cabanillas F
    Blood; 2002 Dec; 100(13):4351-7. PubMed ID: 12393618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
    Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE
    Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience with fludarabine treatment and review of the literature].
    Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
    Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
    Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
    Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
    Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.
    Ma SY; Au WY; Chim CS; Lie AK; Lam CC; Tse E; Leung AY; Liang R; Kwong YL
    Br J Haematol; 2004 Mar; 124(6):754-61. PubMed ID: 15009063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma.
    Saven A; Lee T; Kosty M; Piro L
    J Clin Oncol; 1996 Jul; 14(7):2139-44. PubMed ID: 8683247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial.
    Emmanouilides C; Rosen P; Rasti S; Territo M; Kunkel L
    Hematol Oncol; 1998 Sep; 16(3):107-16. PubMed ID: 10235069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
    McLaughlin P; Estey E; Glassman A; Romaguera J; Samaniego F; Ayala A; Hayes K; Maddox AM; Preti HA; Hagemeister FB
    Blood; 2005 Jun; 105(12):4573-5. PubMed ID: 15741224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
    Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.